FXYD6 Regulates Chemosensitivity by Mediating the Expression of Na+/K+-ATPase α1 and Affecting Cell Autophagy and Apoptosis in Colorectal Cancer

Abstract

Purpose. Chemoresistance is a challenge of improving chemotherapeutic efficacy and prolonging survival time for patients with colorectal cancer (CRC); it is the major cause of frequent recurrence, rapid metastasis, and poor prognosis for CRC patients. FXYD6 is a regulator of Na+/K+-ATPase which is depressed in chemoresistant CRC patients. However, the biological roles of FXYD6 on regulating chemoresistance in CRC are still unclear. Methods. GSE3964 and GSE69657 from GEO DataSets were used to analyze the relationship of genes and chemoresistance. The FXYD6 expression level was detected by western blotting and real-time PCR and also analyzed from TCGA DataSet. To investigate the functional role of FXYD6 and ATP-α1, FXYD6 and ATP-α1 functional cell models were constructed. Drug sensitivity and cell proliferation were performed by MTT assay. Autophagy and apoptosis were conducted by autophagy fluorescence analysis and flow cytometric analysis, respectively. Autophagy and apoptosis markers were tested by western blotting. Results. FXYD6 was downregulated in CRC resistant patients and irinotecan- (Iri-) resistant SW620 cells (SW620/Iri). FXYD6 silence inhibited cell apoptosis and enhanced prosurvival autophagy, whereas FXYD6 overexpression produced the opposite effect which alleviated the drug resistance to irinotecan and oxaliplatin of CRC cells. FXYD6 regulates chemosensitivity by mediating the expression of Na+/K+-ATPase α1 and affecting cell autophagy and apoptosis in colorectal cancer. Conclusion. FXYD6 functions as a chemosensitivity regulator which may predict the curative effect of chemotherapy in colorectal cancer.

ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy

“…To our knowledge, this is the rst study to demonstrate a link between ATP1A1 and resistance to targeted therapy. However, previous studies in other contexts have reported associations between ATP1A1 and chemoresistance [33,34], as well as ATP1A1 and senescence, which could potentially play a role in therapy resistance [35,36]. Since our data were obtained from a small cohort, it will be necessary to con rm these ndings with a larger population to establish whether ATP1A1 levels could be routinely evaluated to better de ne which melanoma patients would bene t from targeted therapy.…”

Meta‐analysis reveals differential gene expression in tetralogy of Fallot versus controls

“…We also noted dysregulation of cardiac hypertrophy through upregulation of F‐box protein 32 (FBXO32) and downregulation of prostaglandin E synthase (PTGES) (Al‐Yacoub et al, 2021; Degousee et al, 2008; Zeng et al, 2013). Downregulated genes also play a role in developmental processes and metabolism, (NKX6‐3) (Alanentalo et al, 2006), cell cycle regulation (TOB2) (Chen et al, 2020), and inhibition of apoptosis (FXYD6, NISCH) (Luo et al, 2021; Mukaddam‐Daher, 2012).…”

Foxa1 mediates eccrine sweat gland development through transcriptional regulation of Na-K-ATPase expression

“…It functions as a receptor for both endogenous and exogenous ligands, activating different signaling pathways associated with cell survival, differentiation, proliferation, and apoptosis among other things. Although Luo and colleagues showed that the small membrane protein FXYD6 could increase NKA expression, whether it can improve sweat gland function remains to be determined ( 40 ).…”